Home Browse Clubs About Tutorial Blog RSS
Article information and data provided by NCBI

Expression of VEGF and PEDF in Choroidal Neovascular Membranes Following Verteporfin Photodynamic Therapy.

by Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Lüke M, Bartz-Schmidt KU, Grisanti S
American journal of ophthalmology.

Article Abstract:

PURPOSE: To examine the impact of photodynamic therapy (PDT) on pigment epithelium derived factor (PEDF) expression in human choroidal neovascularization (CNV) membranes with regard to vascular endothelial growth factor (VEGF) expression. DESIGN: Interventional case series. METHODS: Retrospective review of interventional case series of 42 patients (42 eyes) who underwent removal of CNV. CNV was secondary to age-related macular degeneration (AMD) in all cases. Fifteen patients were treated with PDT, 3 to 246 days before surgery. CNV were stained for CD34, CD105, cytokeratin 18, VEGF, and PEDF. Twenty-seven CNV without previous treatment were used as control. RESULTS: Specimens without pretreatment disclosed varying degrees of vascularization, VEGF, and PEDF expression by different cells. Specimens treated by PDT, three days previously showed mostly occluded vessels lined with damaged endothelial cells (EC). In contrast, specimens excised at later time points after PDT were highly vascularized with healthy EC. This chronology was associated with an impressive VEGF immunoreactivity increased considerably in retinal pigment epithelial cells as well as significantly reduced PEDF expression in EC and stroma. CONCLUSIONS: PDT induces a selective vascular damage in CNV. The effectiveness of PDT, however, seems to be jeopardized by a rebound effect initiated by an enhanced VEGF and reduced PEDF expression in CNV.

Is PDT becoming obsolete?

By: Anonymous - Mon 7/17/2006 PM
This article serves as a plausable explanation of why we get the results we do with PDT for the treatment of exudative AMD. Apparently VEGF rises months after PDT, so it's no wonder that the long term benefit of PDT on visual, FA, and OCT outcomes are generally not an improvement. It will be interesting to see a similar evaluation of retinal treated tissue with kenalog, avastin, macugen, lucentis, and others. Is the VEGF in the retina really going to decrease as claimed?
[ Discuss Article ]     [ Rate Article ]

about ·  mission ·  faq ·  terms ·  privacy ·  contact

Loaded in 0.0616 seconds, using 1.82MB of memory.